Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06662877 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06662877 · ClinicalTrials.gov record · last posted 2024-10-29

Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment

Name: Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment — clinical trial record (NCT06662877)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 2/3

SponsorSun Yat-sen University

Started2024-11-25

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

Biliary tract cancer (BTC) presents with a 5-year survival rate less than 5%. The goal of this clinical trial is to evaluate if Anlotinib plus Nab-Paclitaxels and S-1 as second-line regimen can improve the treatment efficacy in advanced biliary tract cancer (BTC) after progression upon first-line standard treatment, in comparison with standard second-line FOLFOX regimen.

Trial Details

NCT Number	NCT06662877
Lead Sponsor	Sun Yat-sen University Collaborators: CTTQ Pharma
Conditions	Biliary Tract Cancer, Second Line Treatment, Chemotherapy, Tyrosine Kinase Inhibitor
Enrollment	206 participants
Start Date	2024-11-25
Primary Completion	2029-09-01 (estimated)
Study Completion	2029-09-01 (estimated)
Updated on ClinicalTrials.gov	2024-10-29